Table 1. Clinical Characteristics of Patients Who Received Chemotherapy or Declined Chemotherapya.
| chemotherapy (n = 13) |
nonchemotherapy (n = 27) |
|||||
|---|---|---|---|---|---|---|
| variable | noncardiotoxicity (nCtox) | cardiotoxicity (Ctox) | noncardiac damage (nCdam) | cardiac damage (Cdam) | Pa | Pb |
| number, n (female) | 5 (4) | 8 (1) | 8 (5) | 19 (10) | 0.0149* | >0.6375 |
| age, y, median (IQR) | 70 (63–73) | 55 (46–71) | 65 (55–72) | 68 (59–75) | >0.99 | >0.99 |
| LVEF, %, median (IQR) | 59.5 (55.5–64.25) | 58 (58–62.75) | 62 (50–62.5) | 57.5 (53.25–60.5) | >0.99 | >0.99 |
| oncological disease, n (%) | ||||||
| leukemia | 6 (75) | 7 (37) | ||||
| breast cancer | 3 (60) | 2 (25) | 1 (5) | |||
| lymphoma | 1 (13) | 1 (5) | ||||
| prostate cancer | 2 (25) | |||||
| stomach cancer | 1 (20) | 1 (13) | 1 (5) | |||
| lung cancer | 1 (13) | 1 (5) | ||||
| others | 1 (20) | 3 (38) | 8 (42) | |||
| Pro-BNP, pg/mL, median (IQR) | 372.9 (251.3–726.6) | 10346 (8068–17650) | 235.1 (104.6–610.2) | 3035 (1409–7081) | 0.0047 | 0.0055 |
| TnI, ng/mL, median (IQR) | 0.03 (0.03–0.03) | 0.54 (0.0475–0.775) | 0.03 (0.03–0.03) | 0.15 (0.05–0.75) | 0.0267 | 0.0019 |
| CK, U/L, median (IQR) | 38 (20–121) | 173 (99.25–228) | 30 (24–46) | 35.5 (20–204.5) | >0.99 | >0.99 |
| CK-MB, μg/L, median (IQR) | 2 (1.65–2.2) | 5.15 (1.425–9.025) | 1.8 (1.15–2.55) | 2.9 (2.5–5.3) | 0.6125 | >0.99 |
a
Pa, P-value between nCtox and Ctox groups. Pb, P-value between nCdam and Cdam groups. *, P-value = 0.031 after data correction by binary logistic regression.